Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Prevalence of New Genetic Driver in Lung Cancer Shown in Study

Prevalence of New Genetic Driver in Lung Cancer Shown in Study | Lung Cancer Dispatch | Scoop.it

"A line has been drawn from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. 'Everything we know about lung cancer points to the idea that when we find one of these genetic drivers and can target it with a drug, patients will respond and tend to have a good amount of time on drug before it becomes ineffective. Obviously we can't guarantee the effectiveness of targeting the NTRK1 mutation at this point, but everything we know about these kinds of genes makes us extremely hopeful,' says one researcher."


Editor's note: A new targeted therapy treatment may be on the horizon for some lung cancer patients. Targeted therapies work by targeting specific molecules inside cancer cells. Often, these molecules are proteins that are mutated and cause cancer cells to multiply rapidly, contributing to tumor growth. There are several mutated proteins commonly found in non-small cell lung cancer (NSCLC) tumors. For a given patient, these can be detected by molecular testing, and based on the results, doctors can prescribe certain targeted therapy drugs. A newly discovered mutation called NTRK1 is being explored as a potential target for a new targeted therapy. To test the new drug, called LOXO-101, scientists have started a new clinical trial and are enrolling patients whose tumors have NTRK1 mutations.

Cancer Commons's insight:

ScienceDaily  |  May 31, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Team Identifies Novel Biomarker for Head and Neck Cancer, Non-Small Cell Lung Cancer

Team Identifies Novel Biomarker for Head and Neck Cancer, Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

"A team led by a scientist from the Florida campus of The Scripps Research Institute (TSRI) has identified a new biomarker linked to better outcomes of patients with head and neck cancers and non-small cell lung cancer. The work could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.


"The findings, which were published this week online ahead of print by the journal Cancer, focus on a protein called Choline phosphate cytidylyltransferase-α CCT-α or CCTα, an 'antigen' that prompts the immune system to produce antibodies against it."

Cancer Commons's insight:

The Scripps Research Institute  |  Apr 2, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

Quick, Simple Blood Test for Solid Cancers Looks Feasible

Quick, Simple Blood Test for Solid Cancers Looks Feasible | Lung Cancer Dispatch | Scoop.it

"The idea of a general, quick and simple blood test for a diverse range of cancers just came closer to reality with news of a new study published in Nature Medicine.


"Researchers from Stanford University School of Medicine have devised an ultra-sensitive method for finding DNA from cancertumors in the bloodstream.


"Previous research has already shown circulating tumor DNA holds promise as a biomarker for cancer, but existing methods for detecting it are not sufficiently sensitive and do not cover a diverse range of cancers.


"Ways to increase the sensitivity and coverage of such tests exist, but these are cumbersome and time-consuming, and need lots of steps to customize for individual patients, so they are not feasible for use in clinics.


"The new approach promises to change that. It is highly sensitive and specific and should be broadly applicable to a range of cancers, say the researchers."

Cancer Commons's insight:

Medical News Today  |  Apr 7, 2014

more...
Cancer Commons's curator insight, April 7, 2014 4:52 PM

Medical News Today  |  Apr 7, 2014

Cancer Commons's curator insight, April 7, 2014 4:53 PM

Medical News Today  |  Apr 7, 2014

Scooped by Cancer Commons
Scoop.it!

ELCC 2014 News: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening

"Recent results indicate that low-dose computed tomography (LD-CT) screening reduces lung cancer mortality in high risk subjects. However, high false positive rates, costs and potential harm highlight the need for complementary biomarkers. Led by Dr Ugo Pastorino, a group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial. Their findings indicate that microRNA signature classifier has predictive, diagnostic and prognostic value and its combined use with LD-CT may improve screening performance. The results were presented in a proffered papers session at the 4th European Lung Cancer Conference (26-29 March 2014, Geneva, Switzerland)."


Editor's note: LD-CT is a lung cancer detection method that has been shown to reduce risk of death from lung cancer for high-risk patients. However, it sometimes leads to "false-positives," in which suspected cancer later turns out not to be cancer. A new, non-invasive blood test to look for specific kinds of miRNA molecules was shown to be promising as a potential companion test to complement LD-CT screening.

Cancer Commons's insight:

ESMO  |  Mar 28, 2014

more...
No comment yet.